Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are able to understand and sign a written consent form agreeing to take part in the study
- People who have been diagnosed with a specific type of pancreatic cancer called ductal adenocarcinoma, confirmed by a tissue or cell sample test
- People whose cancer has not spread to distant parts of the body, and whose cancer is classified as locally advanced and unable to be surgically removed, based on specific medical staging guidelines (Stage III, T4N0-2M0)
- People whose main pancreatic tumour and any affected nearby lymph nodes are no larger than 7cm across
- People whose pancreatic tumour and affected lymph nodes have not grown into the stomach, duodenum, or small intestine
- People who are in relatively good general health, able to carry out daily activities with little or no limitation (rated 0 or 1 on a standard health scale called the ECOG scale)
- People whose bone marrow is producing enough blood cells, based on specific blood test results (neutrophil count, platelet count, and haemoglobin within required levels)
- People whose liver is functioning well enough, based on specific blood test results for bilirubin and liver enzymes
- People whose kidneys are functioning well enough, based on specific blood test results for creatinine
Who may not be able to join:
- People who have more than one separate tumour in the pancreas
- People whose tumour has grown into a nearby part of the digestive tract
- People who have previously had radiation therapy
- People who have previously had other local treatments for pancreatic cancer, such as high-intensity focused ultrasound (HIFU) or irreversible electroporation
- People whose surrounding healthy organs would receive more radiation than is considered safe during treatment (confirm with trial site)
- People who have had another type of cancer at any point
- People who are unable to understand the purpose of the treatment, or who are unwilling or unable to sign the consent form
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Zheng Wang, MD, PhD, Shanghai Proton and Heavy Ion Center
Phone: +86-02138296666
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
2-year cumulative local regional progression rate (LRP)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.